Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Options for Sustained Delivery

1.25 CME
1.25 CME with ABO CC
$0 FEE
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact

Retina Forum® 2021: Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases - Session on Options for Sustained Delivery


Provider Statement

This continuing medical education activity is provided by Vindico Medical Education

Support Statement

This activity is supported by an educational grant from Genentech, Inc.

Activity Description

Treatment burden and subsequent loss of patient adherence are significant factors associated with less-than-optimal visual acuity gains seen in real-world outcomes in patients with neovascular retinal diseases. Ongoing clinical studies are evaluating novel delivery systems, gene therapies, and agents that enhance dosing intervals while targeting novel pathways with the potential to reduce treatment burden and improve visual acuity outcomes. In this educational activity, Meeting the Vision of Reduced Treatment Burden in Neovascular Retinal Diseases – Session on Options for Sustained Delivery, experts in the field evaluate the evidence demonstrated in clinical trials regarding treatment protocols and their application to real-world practice as well as examine emerging delivery systems and gene therapies that allow for extended intervals between treatments for neovascular retinal diseases.

Target Audience

The intended audience for this activity is comprehensive ophthalmologists, retinal specialists and other health care professionals involved in the management of patients with retinal diseases.

Learning Objectives

Upon successful completion of this activity, participants should be better able to:

  • Evaluate new and emerging modalities that may reduce the burden of anti-vascular endothelial growth factor (VEGF) therapy in neovascular retinal diseases.
  • Describe emerging delivery systems that allow for extended intervals between treatment for neovascular retinal diseases.

Activity Chair

Arshad M. Khanani, MD, MA
Managing Partner
Director of Clinical Research
Director of Fellowship
Sierra Eye Associates
Clinical Associate Professor
University of Nevada
Reno, NV


Dante J. Pieramici, MD
Director, California Retina Research Foundation
Partner, California Retina Consultants
Santa Barbara, CA

Charles C. Wykoff, MD, PhD
Retina Consultants of Houston
Retina Consultants of America
Blanton Eye Institute
Houston Methodist Hospital
Houston, TX


Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP


Vindico Medical Education is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Credit Designation

Vindico Medical Education designates this enduring material for a maximum of 1.25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to satisfy the Lifelong Learning and Self-Assessment requirements for the American Board of Ophthalmology’s Continuing Certification program. It is the CME activity provider’s responsibility to submit learner completion information to ACCME for the purpose of granting credit.

Upon successful completion, learners who opt-in by providing their ABO ID and DOB (MM/DD) will earn credits equivalent to the amount of CME credits claimed for the activity.

This enduring material is approved for 1 year from the date of original release, April 30, 2021, to April 29, 2022.

How to Participate in This Activity and Obtain CME Credit

To participate in this CME activity, you must read the objectives, answer the polling and pretest questions, view the content, and complete the posttest and evaluation. Provide only one (1) correct answer for each question. A satisfactory score is defined as answering 4 of the 5 posttest questions correctly. Upon receipt of the completed materials, if a satisfactory score on the posttest is achieved, Vindico Medical Education will issue an AMA PRA Category 1 Credit(s)™ certificate.


In accordance with the Accreditation Council for Continuing Medical Education’s Standards for Commercial Support, all accredited providers are required to mitigate and disclose to the activity audience the relevant financial relationships of the planners, teachers, and authors involved in the development of accredited content. Individuals have a relevant financial relationship if they have a financial relationship in any amount occurring in the past 12 months with a commercial interest whose products or services are discussed in the accredited activity content over which the individual has control. Relationship information appears below.  

Activity Chair and Faculty report the following relationship(s)

Arshad M. Khanani, MD, MA
Consulting Fee: Adverum, Alcon, Allegro, Allergan, Bausch + Lomb, EyePoint, Gemini Therapeutics, Genentech, Graybug, Gyroscope, Kodiak, Novartis, Opthea, Oxurion, PolyPhotonix, RecensMedical, Regenxbio
Speakers Bureau: Allergan, Genentech, Novartis
Contracted Research: Adverum, Allegro, Allergan, Gemini Therapeutics, Genentech, Graybug, Gyroscope, Iveric Bio, Kodiak, Novartis, Opthea, Oxurion, RecensMedical, Regenxbio

Dante J. Pieramici, MD
Consulting Fee: Adverum, Gemini, Genentech, Regeneron, Regenxbio
Contracted Research: Adverum, Apellis, Gemini, Genentech, Graybug Vision, Gyroscope, Kodiak, NGM, Regeneron, Regenxbio, Stealth BioTherapeutics
Ownership Interest: Gemini

Charles C. Wykoff, MD, PhD
Consulting Fee: Adverum, Allergan, Apellis, Arctic Vision, Arrowhead, Bausch + Lomb, Bayer, Bionic Vision Technologies, Chengdu Kanghong, EyePoint, Genentech, Gyroscope, Iveric Bio, Kato DSRC, Kodiak, Merck, NGM Biopharmaceuticals, Novartis, OccuRx, Ocular Therapeutix, ONL Therapeutics, Oxurion, Palatin, PentaVision, PolyPhotonix, RecensMedical, Regeneron, Regenxbio, Roche, SAI MedPartners, Takeda, Théa Open Innovation, Verana Health
Contracted Research: Adverum, Aerie, Aldeyra, Alimera, Apellis, Bayer, Boehringer Ingelheim, Chengdu Kanghong, Clearside, Gemini Therapeutics, Genentech, Graybug Vision, Ionis, Iveric Bio, Kodiak, LMRI, Neurotech, NGM Biopharmaceuticals, Novartis, Opthea, Outlook Therapeutics, Oxurion, RecensMedical, Regeneron, Regenxbio, Roche, SamChunDang, Santen, Senju, Taiwan Liposome Company, Xbrane Biopharma

Reviewer reports the following relationship(s)

Ronald A. Codario, MD, EMBA, FACP, FNLA, RPVI, CHCP
No relevant financial relationships to disclose.

Vindico Medical Education staff report the following relationship(s)

No relevant financial relationships to disclose.

Signed disclosures are on file at Vindico Medical Education, Office of Medical Affairs and Compliance.

Unlabeled and Investigational Usage

The audience is advised that this continuing medical education activity may contain references to unlabeled uses of US Food and Drug Administration (FDA)–approved products or to products not approved by the FDA for use in the United States. The faculty members have been made aware of their obligation to disclose such usage. All activity participants will be informed if any speakers/authors intend to discuss either non–FDA-approved or investigational use of products/devices.

Copyright Statement

Created and published by Vindico Medical Education, 6900 Grove Road, Building 100, Thorofare, NJ 08086-9447. Telephone: 856-994-9400; Fax: 856-384-6680. Printed in the USA. Copyright © 2021 Vindico Medical Education. All rights reserved. No part of this publication may be reproduced without written permission from the publisher. The material presented at or in any of Vindico Medical Education continuing medical education activities does not necessarily reflect the views and opinions of Vindico Medical Education. Neither Vindico Medical Education nor the faculty endorse or recommend any techniques, commercial products, or manufacturers. The faculty/authors may discuss the use of materials and/or products that have not yet been approved by the US Food and Drug Administration. All readers and continuing education participants should verify all information before treating patients or utilizing any product.

CME Questions?

Contact us at